Antimalarial Drugs Market by Drug Class (Artemisinin Based Combination Therapy, Non Artemisinin Therapies), Route Of Administration (Injectable, Oral), Formulation, Distribution Channel, End User - Global Forecast 2025-2032
Description
The Antimalarial Drugs Market was valued at USD 1.76 billion in 2024 and is projected to grow to USD 1.87 billion in 2025, with a CAGR of 6.10%, reaching USD 2.84 billion by 2032.
Establishing a comprehensive orientation to contemporary antimalarial pharmacotherapies, clinical roles, and healthcare delivery vectors shaping therapeutic strategy
The global response to malaria remains one of the most consequential endeavors in public health, shaped by pharmacological advances, evolving parasite resistance, and shifting healthcare delivery models. Antimalarial drugs occupy a critical position in this landscape, serving both curative and prophylactic roles across endemic and non-endemic regions. This report synthesizes multidisciplinary evidence-clinical, regulatory, supply chain, and payer dynamics-to build a coherent narrative of where antimalarial therapy is today and the strategic inflection points that will define future progress.
Drawing on peer-reviewed clinical literature, regulatory guidance, procurement practices, and field program learnings, the introduction frames key therapeutic classes and administration modalities. It articulates the clinical role of artemisinin-based combination therapies alongside established non-artemisinin agents, and it situates these pharmacotherapies within the contexts of hospital and ambulatory care, retail and online distribution, and formulation innovations that influence adherence and outcomes. Ultimately, this section sets the stage for an evidence-driven discussion of risk, opportunity, and strategic choices for developers, manufacturers, distributors, and public health stakeholders.
Mapping the converging scientific, regulatory, and distributional transformations that are redefining antimalarial therapy development and access across care settings
The antimalarial landscape is undergoing transformative shifts driven by converging scientific, regulatory, and distributional forces that are reconfiguring how therapies are developed, deployed, and accessed. Advances in combination therapies continue to be the cornerstone of clinical strategy, while next-generation molecules and repurposed agents are emerging from translational pipelines with focused resistance mitigation and tolerability profiles. In tandem, diagnostic precision and point-of-care testing have improved case confirmation, shaping prescribing patterns and enabling more targeted use of higher-cost compounds where they deliver clear clinical advantage.
Regulatory pathways and accelerated approval mechanisms have evolved to accommodate urgent therapeutic needs without compromising safety, encouraging adaptive trial designs and real-world evidence integration. Supply chain digitization and the maturation of online pharmacies have broadened distribution reach, yet these same channels demand heightened pharmacovigilance and anti-counterfeit measures. Clinically, there is renewed emphasis on pediatric and pregnant populations, prompting formulation innovation such as dispersible tablets and palatable suspensions. Taken together, these shifts are creating a more dynamic, data-driven market where agility in clinical development, regulatory engagement, and distribution partnerships will determine competitive differentiation and public health impact.
Analyzing how recent United States tariff adjustments are reshaping global procurement, supply chain localization, and supplier contracting for antimalarial medications
Recent tariff policy movements originating from the United States have introduced new considerations for global pharmaceutical trade that reverberate through procurement decisions and supply chain strategies for antimalarial drugs. Tariff adjustments can alter landed costs and contract structures for manufacturers and distributors, prompting stakeholders to reassess sourcing geographies, inventory buffers, and contractual risk-sharing arrangements. Consequently, procurement teams are increasingly incorporating tariff sensitivity analyses into tender evaluations and contingency planning.
Beyond direct cost implications, tariff-driven shifts influence supplier relationships and regional production incentives. Manufacturers may accelerate diversification of manufacturing and packaging footprints to mitigate exposure to trade disruptions, and distributors could pivot towards vendors with more favorable tariff-neutral arrangements. These responses often cascade into longer lead times for new contracts and a renewed focus on regional supply hubs to preserve continuity of public health programs. In addition, trade policy changes heighten the importance of transparent costing and collaborative contracting between public purchasers and manufacturers to avoid unintended constraints on access to essential antimalarial medicines.
Unpacking therapeutic, administration, formulation, distribution, and end-user segmentation to reveal nuanced determinants of access, adherence, and clinical decision-making
A nuanced segmentation framework is essential for understanding heterogeneity in therapeutic preference, delivery modality, and channel dynamics that together determine access and utilization patterns. When examining the market by drug class, artemisinin-based combination therapies occupy a distinct clinical and operational niche, with subsegments such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine offering different efficacy, resistance profiles, and dosing paradigms that influence prescriber choice and national treatment guidelines. Contrastingly, non-artemisinin therapies including chloroquine, mefloquine, primaquine, and quinine remain clinically relevant in specific epidemiological and resistance scenarios, and their utility is often shaped by local parasite sensitivity and safety considerations.
Route of administration and formulation interact to shape patient adherence and therapeutic outcomes. Injectable and oral routes each have distinct use cases: injectable preparations are critical in severe or hospitalized cases, while oral therapies support outpatient and community-level management. Formulation choices-injectables, suspensions, and tablets-determine usability in pediatric populations, ease of distribution in low-resource settings, and cold-chain dependencies. Distribution channel segmentation further refines access dynamics: hospital pharmacies, online pharmacies, and retail pharmacies each present different regulatory oversight, dispensing practices, and patient touchpoints that influence treatment adherence and pharmacovigilance. Finally, end-user segmentation across ambulatory care centers, clinics, and hospitals highlights where demand originates and reveals opportunities for targeted training, stewardship programs, and demand-shaping interventions to improve clinical outcomes and rational drug use.
Examining how regional epidemiology, regulatory frameworks, and supply chain maturity in the Americas, EMEA, and Asia-Pacific drive differentiated access and strategic priorities
Regional dynamics materially influence therapeutic choices, procurement pathways, and operational risk profiles, requiring stakeholders to tailor strategies to local epidemiology, regulatory regimes, and health system capacity. In the Americas, heterogeneous malaria burdens and procurement ecosystems shape a market where targeted control programs coexist with travel-related case management, requiring flexible distribution approaches and strong laboratory-to-clinic linkages to ensure correct diagnosis and treatment selection. In Europe, Middle East & Africa, the interplay between high-burden endemic settings and international donor-supported programs creates a complex funding and procurement environment; here, supply chain robustness, stock visibility, and affordability considerations are paramount to sustain treatment continuity and prevent resistance amplification. In Asia-Pacific, diverse epidemiological zones and rapid shifts in parasite resistance highlight the need for agile therapeutic policies, localized manufacturing capabilities, and strong pharmacovigilance systems to track efficacy and guide guideline updates.
Across these regions, health system maturity, regulatory harmonization, and procurement modalities differ significantly, which affects how therapies are licensed, reimbursed, and distributed. As a result, regional strategic plans must reconcile global clinical guidance with on-the-ground realities, investing in capacity building, point-of-care diagnostics, and distribution infrastructure where gaps threaten access or compound resistance risks. Strategic partnerships between public and private actors, coupled with regional manufacturing and packaging strategies, can reduce lead-time vulnerabilities and align supply with fluctuating demand patterns.
Highlighting industry strategic moves across manufacturing localization, portfolio lifecycle management, and distribution partnerships that underpin competitive advantage in antimalarial therapy delivery
A focused review of corporate activity and strategic behavior among industry participants reveals a landscape defined by clinical pipeline investments, manufacturing scale, and distribution partnerships. Leading pharmaceutical firms and specialized generic manufacturers are optimizing portfolios and production footprints to respond to resistance trends and the need for pediatric-friendly formulations. Strategic alliances with regional manufacturers and contract development and manufacturing organizations support faster localization and mitigate trade exposure risks that can disrupt public health supply chains.
Commercial strategies increasingly emphasize lifecycle management, including reformulations and combination therapies that extend therapeutic relevance and respond to safety or efficacy signals. Companies are also enhancing pharmacovigilance capabilities and investing in digital traceability solutions to protect product integrity across online and informal channels. Meanwhile, distributors and pharmacy chains are developing integrated logistics platforms to improve stock visibility and expedite replenishment, while clinical service providers are expanding training and stewardship programs to preserve drug efficacy. Collectively, these company-level strategies point to a market where operational resilience, regulatory agility, and collaborative procurement will be decisive competitive differentiators.
Practical strategic imperatives and implementation pathways for manufacturers, distributors, and health systems to ensure supply resilience and therapeutic sustainability
Industry leaders must adopt a proactive posture to safeguard access, sustain efficacy, and capitalize on therapeutic innovation. First, companies should prioritize regional manufacturing and packaging partnerships to diversify supply risk and align production with tariff and procurement realities; this approach will shorten lead times and improve responsiveness to public health demand fluctuations. Second, advancing reformulations that enhance pediatric acceptability and simplify dosing will strengthen adherence and expand therapeutic reach in community settings, while parallel investments in rapid diagnostic integration will support targeted prescribing and reduce unnecessary drug pressure.
Third, stakeholders should formalize collaborative contracting and advanced purchase agreements with public purchasers to stabilize supply and share risk in volatile trade environments. Fourth, enhancing end-to-end traceability and pharmacovigilance across hospital, retail, and online channels will protect product quality and support timely safety and efficacy surveillance. Finally, organizations must commit to multi-stakeholder stewardship initiatives that combine clinical education, resistance monitoring, and supply chain transparency to extend drug lifecycles and secure long-term public health impact. Taken together, these actions form a practical playbook for companies and health systems navigating the complex terrain of antimalarial drug delivery.
A methodological synthesis combining systematic clinical evidence review, stakeholder interviews, and operational audits to produce actionable, evidence-based strategic insights
This analysis synthesizes a multidisciplinary methodology designed to balance clinical rigor with operational intelligence. The approach integrates systematic review of peer-reviewed clinical studies, regulatory guidance documents, and public health program reports, complemented by qualitative interviews with supply chain managers, clinicians, and procurement specialists to surface operational constraints and strategic responses. Where appropriate, real-world evidence sources such as pharmacovigilance databases and distribution audit reports were evaluated to triangulate trends in safety signals, adherence challenges, and channel-level leakage.
Analytical techniques emphasize cross-sectional synthesis rather than predictive modeling, focusing on scenario analysis, sensitivity assessment of trade and procurement variables, and qualitative comparative insights across drug classes, routes of administration, formulations, distribution channels, and end-user settings. The research prioritizes transparency in source provenance and clearly delineates assumptions underpinning interpretive judgments, ensuring that conclusions are traceable to the underlying evidence base and suitable for decision-making by clinical and commercial leaders.
A concise synthesis of the strategic crossroads in antimalarial therapy emphasizing alignment of clinical innovation, supply resilience, and collaborative stewardship
In conclusion, the antimalarial therapeutic landscape is at an inflection point defined by clinical innovation, supply chain adaptation, and evolving policy drivers. Artemisinin-based combination therapies remain central to treatment paradigms while non-artemisinin agents retain niche importance where epidemiology dictates. Meanwhile, administration route and formulation choices continue to shape adherence and clinical outcomes, and distribution channels determine access and post-marketing surveillance efficacy. Trade policy shifts and regional operational realities further complicate the environment, underscoring the need for diversified manufacturing strategies and collaborative procurement mechanisms.
To navigate these dynamics effectively, stakeholders must align clinical development with practical distribution considerations, invest in formulation and diagnostic integration that support rational use, and strengthen pharmacovigilance and traceability across all channels. By adopting coordinated, evidence-based strategies, public health programs and private sector actors can sustain therapeutic effectiveness, preserve treatment options, and enhance equitable access to lifesaving antimalarial medicines.
Note: PDF & Excel + Online Access - 1 Year
Establishing a comprehensive orientation to contemporary antimalarial pharmacotherapies, clinical roles, and healthcare delivery vectors shaping therapeutic strategy
The global response to malaria remains one of the most consequential endeavors in public health, shaped by pharmacological advances, evolving parasite resistance, and shifting healthcare delivery models. Antimalarial drugs occupy a critical position in this landscape, serving both curative and prophylactic roles across endemic and non-endemic regions. This report synthesizes multidisciplinary evidence-clinical, regulatory, supply chain, and payer dynamics-to build a coherent narrative of where antimalarial therapy is today and the strategic inflection points that will define future progress.
Drawing on peer-reviewed clinical literature, regulatory guidance, procurement practices, and field program learnings, the introduction frames key therapeutic classes and administration modalities. It articulates the clinical role of artemisinin-based combination therapies alongside established non-artemisinin agents, and it situates these pharmacotherapies within the contexts of hospital and ambulatory care, retail and online distribution, and formulation innovations that influence adherence and outcomes. Ultimately, this section sets the stage for an evidence-driven discussion of risk, opportunity, and strategic choices for developers, manufacturers, distributors, and public health stakeholders.
Mapping the converging scientific, regulatory, and distributional transformations that are redefining antimalarial therapy development and access across care settings
The antimalarial landscape is undergoing transformative shifts driven by converging scientific, regulatory, and distributional forces that are reconfiguring how therapies are developed, deployed, and accessed. Advances in combination therapies continue to be the cornerstone of clinical strategy, while next-generation molecules and repurposed agents are emerging from translational pipelines with focused resistance mitigation and tolerability profiles. In tandem, diagnostic precision and point-of-care testing have improved case confirmation, shaping prescribing patterns and enabling more targeted use of higher-cost compounds where they deliver clear clinical advantage.
Regulatory pathways and accelerated approval mechanisms have evolved to accommodate urgent therapeutic needs without compromising safety, encouraging adaptive trial designs and real-world evidence integration. Supply chain digitization and the maturation of online pharmacies have broadened distribution reach, yet these same channels demand heightened pharmacovigilance and anti-counterfeit measures. Clinically, there is renewed emphasis on pediatric and pregnant populations, prompting formulation innovation such as dispersible tablets and palatable suspensions. Taken together, these shifts are creating a more dynamic, data-driven market where agility in clinical development, regulatory engagement, and distribution partnerships will determine competitive differentiation and public health impact.
Analyzing how recent United States tariff adjustments are reshaping global procurement, supply chain localization, and supplier contracting for antimalarial medications
Recent tariff policy movements originating from the United States have introduced new considerations for global pharmaceutical trade that reverberate through procurement decisions and supply chain strategies for antimalarial drugs. Tariff adjustments can alter landed costs and contract structures for manufacturers and distributors, prompting stakeholders to reassess sourcing geographies, inventory buffers, and contractual risk-sharing arrangements. Consequently, procurement teams are increasingly incorporating tariff sensitivity analyses into tender evaluations and contingency planning.
Beyond direct cost implications, tariff-driven shifts influence supplier relationships and regional production incentives. Manufacturers may accelerate diversification of manufacturing and packaging footprints to mitigate exposure to trade disruptions, and distributors could pivot towards vendors with more favorable tariff-neutral arrangements. These responses often cascade into longer lead times for new contracts and a renewed focus on regional supply hubs to preserve continuity of public health programs. In addition, trade policy changes heighten the importance of transparent costing and collaborative contracting between public purchasers and manufacturers to avoid unintended constraints on access to essential antimalarial medicines.
Unpacking therapeutic, administration, formulation, distribution, and end-user segmentation to reveal nuanced determinants of access, adherence, and clinical decision-making
A nuanced segmentation framework is essential for understanding heterogeneity in therapeutic preference, delivery modality, and channel dynamics that together determine access and utilization patterns. When examining the market by drug class, artemisinin-based combination therapies occupy a distinct clinical and operational niche, with subsegments such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine offering different efficacy, resistance profiles, and dosing paradigms that influence prescriber choice and national treatment guidelines. Contrastingly, non-artemisinin therapies including chloroquine, mefloquine, primaquine, and quinine remain clinically relevant in specific epidemiological and resistance scenarios, and their utility is often shaped by local parasite sensitivity and safety considerations.
Route of administration and formulation interact to shape patient adherence and therapeutic outcomes. Injectable and oral routes each have distinct use cases: injectable preparations are critical in severe or hospitalized cases, while oral therapies support outpatient and community-level management. Formulation choices-injectables, suspensions, and tablets-determine usability in pediatric populations, ease of distribution in low-resource settings, and cold-chain dependencies. Distribution channel segmentation further refines access dynamics: hospital pharmacies, online pharmacies, and retail pharmacies each present different regulatory oversight, dispensing practices, and patient touchpoints that influence treatment adherence and pharmacovigilance. Finally, end-user segmentation across ambulatory care centers, clinics, and hospitals highlights where demand originates and reveals opportunities for targeted training, stewardship programs, and demand-shaping interventions to improve clinical outcomes and rational drug use.
Examining how regional epidemiology, regulatory frameworks, and supply chain maturity in the Americas, EMEA, and Asia-Pacific drive differentiated access and strategic priorities
Regional dynamics materially influence therapeutic choices, procurement pathways, and operational risk profiles, requiring stakeholders to tailor strategies to local epidemiology, regulatory regimes, and health system capacity. In the Americas, heterogeneous malaria burdens and procurement ecosystems shape a market where targeted control programs coexist with travel-related case management, requiring flexible distribution approaches and strong laboratory-to-clinic linkages to ensure correct diagnosis and treatment selection. In Europe, Middle East & Africa, the interplay between high-burden endemic settings and international donor-supported programs creates a complex funding and procurement environment; here, supply chain robustness, stock visibility, and affordability considerations are paramount to sustain treatment continuity and prevent resistance amplification. In Asia-Pacific, diverse epidemiological zones and rapid shifts in parasite resistance highlight the need for agile therapeutic policies, localized manufacturing capabilities, and strong pharmacovigilance systems to track efficacy and guide guideline updates.
Across these regions, health system maturity, regulatory harmonization, and procurement modalities differ significantly, which affects how therapies are licensed, reimbursed, and distributed. As a result, regional strategic plans must reconcile global clinical guidance with on-the-ground realities, investing in capacity building, point-of-care diagnostics, and distribution infrastructure where gaps threaten access or compound resistance risks. Strategic partnerships between public and private actors, coupled with regional manufacturing and packaging strategies, can reduce lead-time vulnerabilities and align supply with fluctuating demand patterns.
Highlighting industry strategic moves across manufacturing localization, portfolio lifecycle management, and distribution partnerships that underpin competitive advantage in antimalarial therapy delivery
A focused review of corporate activity and strategic behavior among industry participants reveals a landscape defined by clinical pipeline investments, manufacturing scale, and distribution partnerships. Leading pharmaceutical firms and specialized generic manufacturers are optimizing portfolios and production footprints to respond to resistance trends and the need for pediatric-friendly formulations. Strategic alliances with regional manufacturers and contract development and manufacturing organizations support faster localization and mitigate trade exposure risks that can disrupt public health supply chains.
Commercial strategies increasingly emphasize lifecycle management, including reformulations and combination therapies that extend therapeutic relevance and respond to safety or efficacy signals. Companies are also enhancing pharmacovigilance capabilities and investing in digital traceability solutions to protect product integrity across online and informal channels. Meanwhile, distributors and pharmacy chains are developing integrated logistics platforms to improve stock visibility and expedite replenishment, while clinical service providers are expanding training and stewardship programs to preserve drug efficacy. Collectively, these company-level strategies point to a market where operational resilience, regulatory agility, and collaborative procurement will be decisive competitive differentiators.
Practical strategic imperatives and implementation pathways for manufacturers, distributors, and health systems to ensure supply resilience and therapeutic sustainability
Industry leaders must adopt a proactive posture to safeguard access, sustain efficacy, and capitalize on therapeutic innovation. First, companies should prioritize regional manufacturing and packaging partnerships to diversify supply risk and align production with tariff and procurement realities; this approach will shorten lead times and improve responsiveness to public health demand fluctuations. Second, advancing reformulations that enhance pediatric acceptability and simplify dosing will strengthen adherence and expand therapeutic reach in community settings, while parallel investments in rapid diagnostic integration will support targeted prescribing and reduce unnecessary drug pressure.
Third, stakeholders should formalize collaborative contracting and advanced purchase agreements with public purchasers to stabilize supply and share risk in volatile trade environments. Fourth, enhancing end-to-end traceability and pharmacovigilance across hospital, retail, and online channels will protect product quality and support timely safety and efficacy surveillance. Finally, organizations must commit to multi-stakeholder stewardship initiatives that combine clinical education, resistance monitoring, and supply chain transparency to extend drug lifecycles and secure long-term public health impact. Taken together, these actions form a practical playbook for companies and health systems navigating the complex terrain of antimalarial drug delivery.
A methodological synthesis combining systematic clinical evidence review, stakeholder interviews, and operational audits to produce actionable, evidence-based strategic insights
This analysis synthesizes a multidisciplinary methodology designed to balance clinical rigor with operational intelligence. The approach integrates systematic review of peer-reviewed clinical studies, regulatory guidance documents, and public health program reports, complemented by qualitative interviews with supply chain managers, clinicians, and procurement specialists to surface operational constraints and strategic responses. Where appropriate, real-world evidence sources such as pharmacovigilance databases and distribution audit reports were evaluated to triangulate trends in safety signals, adherence challenges, and channel-level leakage.
Analytical techniques emphasize cross-sectional synthesis rather than predictive modeling, focusing on scenario analysis, sensitivity assessment of trade and procurement variables, and qualitative comparative insights across drug classes, routes of administration, formulations, distribution channels, and end-user settings. The research prioritizes transparency in source provenance and clearly delineates assumptions underpinning interpretive judgments, ensuring that conclusions are traceable to the underlying evidence base and suitable for decision-making by clinical and commercial leaders.
A concise synthesis of the strategic crossroads in antimalarial therapy emphasizing alignment of clinical innovation, supply resilience, and collaborative stewardship
In conclusion, the antimalarial therapeutic landscape is at an inflection point defined by clinical innovation, supply chain adaptation, and evolving policy drivers. Artemisinin-based combination therapies remain central to treatment paradigms while non-artemisinin agents retain niche importance where epidemiology dictates. Meanwhile, administration route and formulation choices continue to shape adherence and clinical outcomes, and distribution channels determine access and post-marketing surveillance efficacy. Trade policy shifts and regional operational realities further complicate the environment, underscoring the need for diversified manufacturing strategies and collaborative procurement mechanisms.
To navigate these dynamics effectively, stakeholders must align clinical development with practical distribution considerations, invest in formulation and diagnostic integration that support rational use, and strengthen pharmacovigilance and traceability across all channels. By adopting coordinated, evidence-based strategies, public health programs and private sector actors can sustain therapeutic effectiveness, preserve treatment options, and enhance equitable access to lifesaving antimalarial medicines.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increased adoption of single-dose tafenoquine for radical cure of Plasmodium vivax malaria in remote communities
- 5.2. Emergence of pediatric-friendly antimalarial granule formulations improving treatment adherence in sub-Saharan Africa
- 5.3. Growth of generic artemisinin combination therapies facing pricing pressure and regulatory variations across key Asian markets
- 5.4. Rising investments in next-generation triple combination antimalarial regimens to combat multi-drug resistant strains in Southeast Asia
- 5.5. Integration of digital adherence technologies and mobile health platforms to monitor antimalarial treatment outcomes in rural zones
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Antimalarial Drugs Market, by Drug Class
- 8.1. Artemisinin Based Combination Therapy
- 8.1.1. Artemether Lumefantrine
- 8.1.2. Artesunate Amodiaquine
- 8.1.3. Artesunate Mefloquine
- 8.1.4. Dihydroartemisinin Piperaquine
- 8.2. Non Artemisinin Therapies
- 8.2.1. Chloroquine
- 8.2.2. Mefloquine
- 8.2.3. Primaquine
- 8.2.4. Quinine
- 9. Antimalarial Drugs Market, by Route Of Administration
- 9.1. Injectable
- 9.2. Oral
- 10. Antimalarial Drugs Market, by Formulation
- 10.1. Injectables
- 10.2. Suspensions
- 10.3. Tablets
- 11. Antimalarial Drugs Market, by Distribution Channel
- 11.1. Hospital Pharmacies
- 11.2. Online Pharmacies
- 11.3. Retail Pharmacies
- 12. Antimalarial Drugs Market, by End User
- 12.1. Ambulatory Care Centers
- 12.2. Clinics
- 12.3. Hospitals
- 13. Antimalarial Drugs Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Antimalarial Drugs Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Antimalarial Drugs Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Abbott Laboratories
- 16.3.2. Alkem Laboratories
- 16.3.3. Alliance Pharma
- 16.3.4. Alvizia Health Care
- 16.3.5. Bayer AG
- 16.3.6. Cipla Inc.
- 16.3.7. Dr. Reddy's Laboratories
- 16.3.8. F. Hoffmann-La Roche Ltd.
- 16.3.9. GlaxoSmithKline plc
- 16.3.10. Glenmark Pharmaceuticals
- 16.3.11. Hikma Pharmaceuticals PLC
- 16.3.12. Ipca Laboratories Ltd.
- 16.3.13. Lincoln Pharmaceuticals
- 16.3.14. Lupin Limited
- 16.3.15. Merck KGaA
- 16.3.16. Mylan
- 16.3.17. Novartis AG
- 16.3.18. Pfizer Inc.
- 16.3.19. Sanofi Group
- 16.3.20. Strides Pharma Science Limited
- 16.3.21. Sun Pharmaceutical Industries Ltd.
- 16.3.22. Takeda Pharmaceutical Company
- 16.3.23. Teva Pharmaceuticals Industries Ltd.
- 16.3.24. Zydus Group
- 16.3.25. Zydus Lifesciences Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
